Master dataINID | Criterion | Field | Content |
---|
| Type of IP right | SART | Patent |
| Status | ST | Pending/in force |
21 | DE file number | DAKZ | 60 2009 065 194.3 |
96 | EP file number | EAKZ | 19 20 7534.9 |
97 | EP publication number | EPN | 3628319 |
54 | Designation/title | TI | BEHANDLUNG VON HEPATISCHER ENZEPHALOPATHIE UNTER VERWENDUNG VON RIFAXIMIN |
51 | IPC main class | ICM (ICMV) | A61K 31/437 (2006.01) |
51 | IPC secondary class(es) | ICS (ICSV) | A61K 45/06 (2006.01), A61K 31/08 (2006.01), A61K 31/352 (2006.01), A61K 31/4164 (2006.01), A61K 31/426 (2006.01), A61K 31/4439 (2006.01), A61K 31/606 (2006.01), A61K 31/7016 (2006.01), A61K 31/785 (2006.01), A61K 38/14 (2006.01), A61K 38/31 (2006.01), A61P 1/16 (2006.01), A61K 31/395 (2006.01) |
22 | DE application date | DAT | Oct 2, 2009 |
96 | EP application date | EAT | Oct 2, 2009 |
43 | Date of first publication | OT | Apr 1, 2020 |
| Date of publication of grant | PET | Feb 14, 2024 |
71/73 | Applicant/owner | INH | Salix Pharmaceuticals, Inc., Raleigh, NC, US |
72 | Inventor | IN | FORBES, William, Raleigh, NC 27164, US |
74 | Representative | VTR | Kraus & Lederer PartGmbB, 80539 München, DE |
| Address for service | | Kraus & Lederer PartGmbB, 80539 München, DE |
33 31 32
| Foreign priority | PRC PRNA PRDA
| US 102349 P Oct 2, 2008
|
| Due date | FT FG | Oct 31, 2025 Annual fee for the 17th year
Patent fees |
| Patent division in charge | | 44 |
97 | EP language of publication | ELANG | EN - Englisch |
84 | Designated EP contracting states | EDS | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR |
| Published EP/WO documents | EPWOPN | Original document:
EP000003628319A1 Searchable text:
EP000003628319A1 Original document:
EP000003628319B1 Searchable text:
EP000003628319B1 |
43 | Date of first publication | EVT | Apr 1, 2020 |
| Date of the first transfer into DPMAregister | EREGT | Apr 1, 2020 |
| Date of the (most recent) update in DPMAregister | REGT | Nov 29, 2024 (Show all update days)(Hide all update days)- Nov 29, 2024
- Procedures: Opposition procedure, Opposition filed, 04.11.2024: changed
- Nov 21, 2024
- Procedures: Opposition procedure, Opposition filed, 04.11.2024: new
- Sep 27, 2024
- Jul 24, 2024
- St.36: changed (technical change)
- Apr 27, 2024; Mar 23, 2024; Feb 15, 2024; Feb 8, 2024; Jan 30, 2024; Jan 25, 2024; Nov 23, 2023
- Historical data not available for this/these date(s)
- Apr 1, 2020
- Date of the first transfer into DPMAregister
|
View procedures New applicant/owner details (No.: 5)INID | Criterion | Field | Content
Close details
|
---|
| Type of procedure | VART | New applicant/owner details |
| Legal/procedural status | VST | New applicant/owner details |
| Date of legal/procedural status | VSTT | Mar 22, 2024 |
| Issue number | HN | 18 |
| Year | PJ | 2024 |
| Publication date | VT | May 2, 2024 |
| Type of publication | PART | Bibliographic data |
| Part | HT | Part 3 |
71/73 | Applicant/owner | INH | Salix Pharmaceuticals, Inc., Raleigh, NC, US |
71/73 | Previous applicant/owner | INHF | Salix Pharmaceuticals, Ltd., Bridgewater, NJ, US |
| Date of update of the procedure | REGT | Apr 27, 2024 |